Neuroendocrine differentiation of prostate cancer is not systematically associated with increased 18f-fdg uptake
Articolo
Data di Pubblicazione:
2021
Abstract:
Neuroendocrine differentiation (NED) of prostate cancer represents an acknowledged predictor of resistant and more aggressive disease. NED can be functionally exploited in vivo using PET/CT imaging with somatostatin analogs radiolabeled with 68Ga. Many previous reports have shown that 18F-FDG PET/CT should also be used in cases such as guiding management, as NED is systematically associated with increased glycolysis. We hereby discuss the case of a metastatic prostate cancer patient in which 68Ga-Dotatoc PET/CT revealed the occurrence of NED with low FDG-avidity.
Tipologia CRIS:
03A-Articolo su Rivista
Keywords:
18F-Fluorodeoxyglucose; 68Ga-Dotatoc; Metastatic castration-resistant prostate cancer; Neuroendocrine differentiation; Positron emission tomography
Elenco autori:
Bauckneht M.; Morbelli S.; Miceli A.; Rebuzzi S. E.; Fornarini G.
Link alla scheda completa:
Pubblicato in: